The report covers the analysis and forecast of the circulating tumor cell (CTC) diagnostics market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Bn).
The study provides a detailed view of the circulating tumor cell (CTC) diagnostics market, by segmenting it based on, technology, application, end-user and regional demand. The technology segment includes CTC enrichment, CTC detection and CTC analysis. The CTC enrichment section can be sub segmented into microchips, single spiral micro channel, positive (both in-vivo and ex-vivo types) and negative selection; while on the other hand, CTC detection procedure consists of molecular-based (RNA) technologies, optical-based flow cytometry, EPISPOT in-vitro cell culture, in-vitro cell invasion assay and different xenotransplantation models.
Based on application, the market can be classified into different kinds of cancer viz. breast cancer, lung cancer, colorectal cancer, prostate cancer and others (skin cancer, pancreatic cancer and ovarian cancer).
End-User segment includes biotechnological research centers, hospitals and clinics, pharmaceuticals and academic research institutions.
Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Market dynamics for each region has been provided in the report.
The competitive profiling of the key players in the global circulating tumor cell (CTC) diagnostics market across five broad geographic regions is included in the study. These include different business strategies adopted by the leading players and their recent developments, as in the field of market.
A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the circulating tumor diagnostics market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the circulating tumor cell (CTC) diagnostics market.
The report provides the size of the global circulating tumor cell (CTC) diagnostics market from 2017 and the forecast for the next eight years up to 2025. The size of the global circulating tumor cell (CTC) diagnostics market is provided in terms of revenue. Market revenue is defined in US$ Million. The market dynamics prevalent in North America, Europe, Middle East and Africa, Latin America and Asia Pacific have been considered in estimating the growth of the global market.
The market estimates for this study have been based on revenue being derived through regional pricing trends. Demand for circulating tumor cell (CTC) diagnostics has been derived by analyzing the global and regional demand for each product with its respective functions. Forecasts have been based on expected demand from the product type of circulating tumor cell (CTC) diagnostics. We have used the bottom-up approach to estimate the global revenue of the circulating tumor cell (CTC) diagnostics market, split into regions. Based on technology, application and end-user segments, we have summed up the individual revenues from all the regions to achieve the global revenue for circulating tumor cell (CTC) diagnostics. End-user split of the market has been derived using a bottom-up approach for each regional market separately, with the global end-user segment split being an integration of regional estimates. Various companies were considered for the market share analysis, based on their innovation, application and revenue generation. In the absence of specific data related to the sales of circulating tumor cell (CTC) diagnostics by privately held companies; calculated assumptions have been made in view of the company’s penetration and regional presence across product and end-user segments.
The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Advanced Cell Diagnostics, AVIVA Biosciences Corp., Biocept, Inc., Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences Inc., RareCells USA, STEM CELL Technologies, Veridex LLC and Vitatex Inc. among others.
The Global Circulating Tumor Cell (CTC) Diagnostics market has been segmented into:
Circulating Tumor Cell (CTC) Diagnostics Market: By Technology
- Microchips
- Single Spiral Micro Channel
- Ex-vivo Positive Selection
- In-Vivo Positive Selection
- Negative Selection
- Molecular (RNA) Based Technologies
- Optical-Based Flow Cytometry
- EPISPOT in-vitro Cell Culture
- In-Vitro Cell Invasion Assay
- Xeno transplantation models
Circulating Tumor Cell (CTC) Diagnostics Market: By Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate cancer
- Others (Skin Cancer, Pancreatic Cancer and Ovarian Cancer)
Circulating Tumor Cell (CTC) Diagnostics Market: By End-User
- Biotechnological Research Centers
- Hospitals and Clinics
- Pharmaceuticals
- Academic Research Institutions
Circulating Tumor Cell (CTC) Diagnostics Market: By Geography
- North America
- Europe
- U.K.
- Italy
- France
- Germany
- Russia
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Rest of Latin America
1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET SNAPSHOT
3.2 GLOBAL CTC DIAGNOSTICS MARKET REVENUE, 2017 – 2025 (US$ BN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS, %, 2016
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY TECHNOLOGY
5.1 OVERVIEW
5.2 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) ENRICHMENT, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.3 GLOBAL CTC DIAGNOSTICS MARKET FOR CTC (TUMOR) DETECTION, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
5.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR CTC ANALYSIS; VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BREAST CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR LUNG CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR COLORECTAL CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PROSTATE CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
6.6 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR OTHERS (SKIN CANCER, PANCREATICCANCER & OVARIAN CANCER) CANCER, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY END-USER
7.1 OVERVIEW
7.2 GLOBAL CTC DIAGNOSTICS MARKET FOR BIOTECHNOLOGICAL RESEARCH CENTERS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.3 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR , HOSPITALS & CLINICS, VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.4 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR PHARMACEUTICALS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
7.5 GLOBAL GLOBAL CTC DIAGNOSTICS MARKET FOR, ACADEMIC RESEARCH INSTITUTIONS , VOLUME & REVENUE, 2017–2025, (UNITS) (US$ BN)
8 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY GEOGRAPHY
8.1 NORTH AMERICA
8.1.1 MARKET DYNAMICS
8.1.1.1 Drivers
8.1.1.2 Restraints
8.1.1.3 Opportunity
8.1.2 U.S.
8.1.3 CANADA
8.1.4 MEXICO
8.2 EUROPE
8.2.1 MARKET DYNAMICS
8.2.1.1 Drivers
8.2.1.2 Restraints
8.2.1.3 Opportunity
8.2.2 U.K.
8.2.3 ITALY
8.2.4 FRANCE
8.2.5 GERMANY
8.2.6 RUSSIA
8.2.7 SPAIN
8.2.8 REST OF EUROPE
8.3 ASIA PACIFIC
8.3.1 MARKET DYNAMICS
8.3.1.1 Drivers
8.3.1.2 Restraints
8.3.1.3 Opportunity
8.3.2 INDIA
8.3.3 CHINA
8.3.4 JAPAN
8.3.5 AUSTRALIA
8.3.6 REST OF ASIA PACIFIC
8.4 MIDDLE EAST AND AFRICA
8.4.1 MARKET DYNAMICS
8.4.1.1 Drivers
8.4.1.2 Restraints
8.4.1.3 Opportunity
8.4.2 GCC
8.4.3 SOUTH AFRICA
8.4.4 REST OF MIDDLE EAST AND AFRICA
8.5 LATIN AMERICA
8.5.1 MARKET DYNAMICS
8.5.1.1 Drivers
8.5.1.2 Restraints
8.5.1.3 Opportunity
8.5.2 BRAZIL
8.5.3 REST OF LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 NEW PRODUCT LAUNCHES
10 GLOBAL CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 ADNAGEN AG
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 OUR COMPANY VIEW
10.3 ADVANCED CELL DIAGNOSTICS
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 OUR COMPANY VIEW
10.4 AVIVA BIOSCIENCES CORP.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 OUR COMPANY VIEW
10.5 BIOCEPT, INC.
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 OUR COMPANY VIEW
10.6 CELULA, INC.
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 OUR COMPANY VIEW
10.7 CYNVENIO BIOSYSTEMS, INC.
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 OUR COMPANY VIEW
10.8 EPIC SCIENCES, INC.
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 OUR COMPANY VIEW
10.9 FLUXION BIOSCIENCES, INC.
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 OUR COMPANY VIEW
10.10 MENARINI SILICON BIOSYSTEMS, INC.
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.10.6 OUR COMPANY VIEW
10.11 NANOSTRING TECHNOLOGIES, INC.
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS & SERVICES
10.11.3 KEY STRATEGY
10.11.4 RECENT DEVELOPMENTS
10.11.5 SWOT ANALYSIS
10.11.6 OUR COMPANY VIEW
10.12 RARECELLS, USA
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS & SERVICES
10.12.3 KEY STRATEGY
10.12.4 RECENT DEVELOPMENTS
10.12.5 SWOT ANALYSIS
10.12.6 OUR COMPANY VIEW
10.13 VERIDEX , LLC.
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS & SERVICES
10.13.3 KEY STRATEGY
10.13.4 RECENT DEVELOPMENTS
10.13.5 SWOT ANALYSIS
10.13.6 OUR COMPANY VIEW
10.14 VITATEX INC.
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS & SERVICES
10.14.3 KEY STRATEGY
10.14.4 RECENT DEVELOPMENTS
10.14.5 SWOT ANALYSIS
10.14.6 OUR COMPANY VIEW
.12.2 PRODUCTS & SERVICES
10.12.3 KEY STRATEGY
10.12.4 RECENT DEVELOPMENTS
10.12.5 SWOT ANALYSIS
10.12.6 OUR COMPANY VIEW
10.13 VERIDEX , LLC.
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS & SERVICES
10.13.3 KEY STRATEGY
10.13.4 RECENT DEVELOPMENTS
10.13.5 SWOT ANALYSIS
10.13.6 OUR COMPANY VIEW
10.14 VITATEX INC.
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS & SERVICES
10.14.3 KEY STRATEGY
10.14.4 RECENT DEVELOPMENTS
10.14.5 SWOT ANALYSIS
10.14.6 OUR COMPANY VIEW
+1 888 709 8757
Chat With Us